WO2003039468A3 - Antimnemonic therapy for hypermemory syndromes - Google Patents
Antimnemonic therapy for hypermemory syndromes Download PDFInfo
- Publication number
- WO2003039468A3 WO2003039468A3 PCT/US2002/035524 US0235524W WO03039468A3 WO 2003039468 A3 WO2003039468 A3 WO 2003039468A3 US 0235524 W US0235524 W US 0235524W WO 03039468 A3 WO03039468 A3 WO 03039468A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimnemonic
- therapy
- hypermemory
- syndromes
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002465869A CA2465869A1 (en) | 2001-11-06 | 2002-11-05 | Antimnemonic therapy for hypermemory syndromes |
AU2002354041A AU2002354041A1 (en) | 2001-11-06 | 2002-11-05 | Antimnemonic therapy for hypermemory syndromes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33271301P | 2001-11-06 | 2001-11-06 | |
US60/332,713 | 2001-11-06 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003039468A2 WO2003039468A2 (en) | 2003-05-15 |
WO2003039468A3 true WO2003039468A3 (en) | 2003-10-23 |
WO2003039468B1 WO2003039468B1 (en) | 2003-11-27 |
Family
ID=23299527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/035524 WO2003039468A2 (en) | 2001-11-06 | 2002-11-05 | Antimnemonic therapy for hypermemory syndromes |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002354041A1 (en) |
CA (1) | CA2465869A1 (en) |
WO (1) | WO2003039468A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8118722B2 (en) | 2003-03-07 | 2012-02-21 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
US7153256B2 (en) | 2003-03-07 | 2006-12-26 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
US7601115B2 (en) | 2004-05-24 | 2009-10-13 | Neuronetics, Inc. | Seizure therapy method and apparatus |
DE602005027714D1 (en) * | 2004-09-20 | 2011-06-09 | Sinai School Medicine | USE OF MEMANTINE (NAMENDA) FOR THE TREATMENT OF AUTISM, FORCED BEHAVIOR AND IMPULSIVITY |
US7857746B2 (en) | 2004-10-29 | 2010-12-28 | Nueronetics, Inc. | System and method to reduce discomfort using nerve stimulation |
US7396326B2 (en) | 2005-05-17 | 2008-07-08 | Neuronetics, Inc. | Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators |
US7824324B2 (en) | 2005-07-27 | 2010-11-02 | Neuronetics, Inc. | Magnetic core for medical procedures |
WO2008045641A2 (en) * | 2006-10-10 | 2008-04-17 | The University Of Chicago | Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent |
US20110046120A1 (en) * | 2006-10-26 | 2011-02-24 | Mclean Hospital Corporation | Treatment of impulse control disorders |
IL292725A (en) * | 2012-07-12 | 2022-07-01 | Emalex Biosciences Inc | Fused benzazepines for treatment of tourette's syndrome |
WO2016061320A2 (en) * | 2014-10-15 | 2016-04-21 | Rowan University | Timber therapy for post-traumatic stress disorder |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
US5863934A (en) * | 1995-09-21 | 1999-01-26 | Amy F. T. Arnsten | Use of lofexidine in the treatment of behavioral disorders |
US5962494A (en) * | 1991-06-26 | 1999-10-05 | Sepracor Inc. | Methods for treating behavioral and other disorders using optically pure R(+) ondansetron |
-
2002
- 2002-11-05 WO PCT/US2002/035524 patent/WO2003039468A2/en not_active Application Discontinuation
- 2002-11-05 AU AU2002354041A patent/AU2002354041A1/en not_active Abandoned
- 2002-11-05 CA CA002465869A patent/CA2465869A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962494A (en) * | 1991-06-26 | 1999-10-05 | Sepracor Inc. | Methods for treating behavioral and other disorders using optically pure R(+) ondansetron |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
US5863934A (en) * | 1995-09-21 | 1999-01-26 | Amy F. T. Arnsten | Use of lofexidine in the treatment of behavioral disorders |
Also Published As
Publication number | Publication date |
---|---|
CA2465869A1 (en) | 2003-05-15 |
WO2003039468A2 (en) | 2003-05-15 |
WO2003039468B1 (en) | 2003-11-27 |
AU2002354041A1 (en) | 2003-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002002624A3 (en) | B7-like molecules and uses thereof | |
WO2003039468A3 (en) | Antimnemonic therapy for hypermemory syndromes | |
WO2002024891A3 (en) | B7-like molecules and uses thereof | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
HK1123741A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine) | |
IL163102A (en) | Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders | |
WO2003060071A3 (en) | Albumin fusion proteins | |
WO2000054813A3 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
AU2003289888A1 (en) | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | |
WO2006018632A3 (en) | Cell therapy with exo 1 | |
WO2002024234A3 (en) | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye | |
DE60214846D1 (en) | Use of mGLuR5 antagonists for the manufacture of medicaments for the treatment of sensitive X syndromes, autism and mental retardation | |
UA82828C2 (en) | The use of enantiomeric pure escitalopram for treatment of depression | |
CA2436540A1 (en) | Pharmaceutical compositions based on anticholinergics and corticosteroids | |
WO2001013905A3 (en) | Methods for the treatment of mental and vascular disorders | |
WO2001068854A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
IL174303A0 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
WO2004098536A3 (en) | Anti-viral activity of cathelicidin peptides | |
WO2006028492A3 (en) | hC1Q/TNF7 AND USES THEREOF | |
WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
ZA200400313B (en) | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine. | |
WO2001042474A3 (en) | Interferon-like molecules and uses thereof | |
HK1063601A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
WO2005123113A3 (en) | Interferon compositions and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
B | Later publication of amended claims |
Free format text: 20030818 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2465869 Country of ref document: CA |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |